Valuation : EXACT Therapeutics

Market Cap	48.4M 5.2M 4.48M 4.21M 3.85M 7.2M 491M 7.22M 49.79M 19.32M 252M 19.54M 19.12M 812M	P/E 2024	-2.49x	P/E 2025	-1x
Enterprise Value	24.48M 2.63M 2.27M 2.13M 1.95M 3.64M 249M 3.65M 25.19M 9.78M 128M 9.89M 9.67M 411M	EV / Sales 2024	-	EV / Sales 2025	1,074,437,000x
Free-Float	30.97%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Latest news : EXACT Therapeutics

09-03	EXACT Therapeutics AS Reports Earnings Results for the Half Year Ended June 30, 2026	CI
06-30	Exact Therapeutics to Delist from Euronext Growth Oslo in October	MT
06-26	EXACT Therapeutics AS Gets Positive Safety Review For 60 ?l/Kg Dose In Phase 2 ENACT Trial	RE
06-26	EXACT Therapeutics Issues Positive Second Safety Read-Out From Phase 2 ENACT Trial In Pancreatic Cancer	CI
06-17	Euronext Oslo Børs Receives Exact Therapeutics' Delisting Application	MT
05-29	Exact Therapeutics' Board Proposes Delisting from Euronext Growth Oslo	MT
04-09	EXACT Therapeutics AS Reports Earnings Results for the Full Year Ended December 31, 2025	CI
03-03	Exact Therapeutics as Doses First Patient in Europe in Phase 2 Enact Trial for Locally Advanced Pancreatic Cancer	CI
01-27	Exact Therapeutics as Announces Positive Initial Safety Read-Out from the Phase 2 Enact Trial in Pancreatic Cancer	CI
11-24	Exact Therapeutics introduces new long-term incentive program	RE
25-09-25	EXACT Therapeutics AS Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-09-25	Exact Therapeutics H1 operating loss widens to NOK 45.9 million	RE
25-08-12	EXACT Therapeutics AS to Present at the European Society for Medical Oncology Congress 2025	CI

More news

Press Releases : EXACT Therapeutics

09-04	EXACT Therapeutics publishes shareholder information regarding the delisting	AQ
09-03	EXACT Therapeutics first half 2026 interim report	AQ
08-31	EXACT Therapeutics AS - Issuance of share options	AQ
07-02	EXACT Therapeutics : Oslo Stock Exchange approves application to delist EXACT Therapeutics’ shares	PU
06-30	EXACT Therapeutics AS - Removal from trading	AQ

More press releases

Managers and Directors : EXACT Therapeutics

Manager	Title	Age	Since
Per Walday CEO	Chief Executive Officer	66	2022-06-05
Svein Kvåle COO	Chief Operating Officer	-	2011-12-31
John Edminson DFI	Director of Finance/CFO	-	2022-09-30

Director	Title	Age	Since
Masha Paule Nathalie Strømme CHM	Chairman	55	2018-06-21
Anders Wold CHM	Chairman	-	2022-06-07
Ann-Tove Kongsnes BRD	Director/Board Member	59	-

More insiders

Other Biotechnology & Medical Research

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
EXACT THERAPEUTICS	-1.92%	+10.07%	-69.15%	-94.12%	5.2M
LONZA GROUP AG	-2.54%	-2.84%	-1.77%	+14.33%	48.93B
REVOLUTION MEDICINES, INC.	-0.40%	+1.03%	+418.57%	+527.30%	45.01B
IQVIA HOLDINGS INC.	-1.42%	+2.30%	+42.67%	+22.37%	44.07B
BEONE MEDICINES AG	-1.22%	-2.31%	+4.82%	+77.49%	40.73B
CELLTRION, INC.	+0.53%	-1.36%	+16.87%	+46.82%	33.52B
ASCENDIS PHARMA A/S	-0.21%	+9.14%	-	-	17.77B
MEDPACE HOLDINGS, INC.	-0.35%	-1.56%	+21.42%	+120.75%	16.5B
EUROFINS SCIENTIFIC SE	-1.01%	+0.50%	+13.91%	+31.83%	14.67B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.65%	-1.03%	+75.93%	+41.12%	13.77B
Average	-1.02%	+1.49%	+58.14%	+87.54%	27.5B
Weighted average by Cap.	-1.03%	+0.11%	+89.42%	+128.97%

See all sector performances

Exact Therapeutics AS is a Norway-based clinical-stage biopharmaceutical company, which develops ultrasound-mediated technology platform for targeted therapeutic enhancement Acoustic Cluster Therapy (ACT). ACT sonoporation is an approach to ultrasound-mediated, targeted drug enhancement with the potential to significantly amplify the clinical utility of a wide range of therapeutic agents across a multitude of indications including within cancer (chemotherapy, immunotherapy), infectious diseases, and neurological conditions. The Company's purpose is to extend and enrich patient lives through targeted therapeutic enhancement. It is done through harnessing the power of ultrasound in combination with ACT formulation.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-09-04	NOK 0.7650	-1.92%	4,000
26-09-03	NOK 0.7800	+6.85%	33,930
26-09-02	NOK 0.7300	-2.67%	81,282
26-09-01	NOK 0.7500	-2.60%	25,156
26-08-31	NOK 0.7700	+10.79%	21,233

Real-time Oslo Bors

More quotes

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

Market Closed - Oslo Bors 10:45:00 2026-09-04 EDT			5-day change	1st Jan Change
0.7650 ^NOK	-1.92%		+10.07%	-44.57%

Markets		Quality
Oslo Bors	EXTX	Real-time
Deutsche Boerse AG	56F	Delayed

1 day	-1.92%
1 week	+10.07%
Current month	-0.65%
1 month	+3.38%
3 months	+1.32%
6 months	-56.03%
Current year	-44.57%

1 week	0.73	0.8
1 month	0.69	0.8
Current year	0.58	2.7
1 year	0.58	2.78
3 years	0.58	20
5 years	0.58	22
10 years	0.58	53.59

Date	Insider	Type	Main position	Quantity	% Market Cap.
1/4/23	Anders Wold	Buy	Chairman	2,500	0.0083%
1/4/23	Svein Kvåle	Buy	Founder	2,500	0.0083%
1/4/23	John Edminson	Buy	Chief Financial Officer	2,500	0.0083%

EXACT Therapeutics Stock

Stocks

EXTX

NO0010852213

Biotechnology & Medical Research

Valuation : EXACT Therapeutics

Chart: EXACT Therapeutics

Latest news : EXACT Therapeutics

Press Releases : EXACT Therapeutics

Quotes and Performance

Price Extremes

Managers and Directors : EXACT Therapeutics

Latest insider transactions

Other Biotechnology & Medical Research

Financials

Company Profile

Quotes

	2024	2025
Net sales	-	0.06 0.01 0.01 0.01 0 0.01 0.6 0.01 0.06 0.02 0.31 0.02 0.02 0.99
Net income	-52.33M -5.63M -4.84M -4.56M -4.16M -7.79M -531M -7.81M -53.84M -20.89M -273M -21.13M -20.67M -878M	-86.97M -9.35M -8.05M -7.57M -6.92M -12.94M -883M -12.98M -89.48M -34.72M -453M -35.12M -34.35M -1.46B
Net Debt	-98.89M -10.63M -9.15M -8.61M -7.87M -14.71M -1B -14.75M -102M -39.48M -515M -39.93M -39.06M -1.66B	-23.91M -2.57M -2.21M -2.08M -1.9M -3.56M -243M -3.57M -24.6M -9.55M -125M -9.66M -9.45M -401M